FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1483-1484 April 7, 2005 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The evidence of the effectiveness of statins in the treatment of stable coronary heart disease (CHD) continues to grow. Large-scale, randomized, secondary-prevention trials involving patients with CHD have shown that statins reduce the clinical consequences of atherosclerosis, including death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina pectoris and heart failure, as well as the need for coronary revascularization. Current guidelines recommend a low-density lipoprotein (LDL) cholesterol level of less than 100 mg per deciliter (2.6 mmol per liter) as the goal for patients with stable CHD and a goal of 70 mg per deciliter (1.8 . . . [Full Text of this Article]

Source Information

From the University of Michigan School of Medicine, Ann Arbor.

This editorial was published at www.nejm.org on March 8, 2005.

This article has been cited by other articles:

• Hayward, R. A., Krumholz, H. M., Zulman, D. M., Timbie, J. W., Vijan, S. (2010). Optimizing Statin Treatment for Primary Prevention of Coronary Artery Disease. ANN INTERN MED 152: 69-77 [Abstract] [Full Text]  
• Levitt, E. S., Clark, M. J., Jenkins, P. M., Martens, J. R., Traynor, J. R. (2009). Differential Effect of Membrane Cholesterol Removal on {micro}- and {delta}-Opioid Receptors: A PARALLEL COMPARISON OF ACUTE AND CHRONIC SIGNALING TO ADENYLYL CYCLASE. J. Biol. Chem. 284: 22108-22122 [Abstract] [Full Text]  
• Lavie, C. J., Milani, R. V., O'Keefe, J. H. (2007). Statin Wars-Emphasis on Potency vs Event Reduction and Safety?. Mayo Clin Proc. 82: 539-542 [Full Text]  
• de Lusignan, S., Belsey, J., Hague, N., Dhoul, N., van Vlymen, J. (2006). Audit-based education to reduce suboptimal management of cholesterol in primary care: a before and after study. J Public Health (Oxf) 28: 361-369 [Abstract] [Full Text]  
• Cohen, J. S., East, J. E., Elkind, M. S.V., Khan, N. A., Mascitelli, L., Pezzetta, F., Welch, K.M.A., the SPARCL Investigators, , Kent, D. (2006). Statin Therapy after Stroke or Transient Ischemic Attack. NEJM 355: 2368-2371 [Full Text]  
• Cannon, C. P., Steinberg, B. A., Murphy, S. A., Mega, J. L., Braunwald, E. (2006). Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy. J Am Coll Cardiol 48: 438-445 [Abstract] [Full Text]  
• (2005). Lower LDL Target for Stable CHD Patients?. Journal Watch Cardiology 2005: 10-10 [Full Text]  
• Pedersen, T. R., Faergeman, O., Kastelein, J. J. P., Olsson, A. G., Tikkanen, M. J., Holme, I., Larsen, M. L., Bendiksen, F. S., Lindahl, C., Szarek, M., Tsai, J., for the Incremental Decrease in End Points Through, (2005). High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial. JAMA 294: 2437-2445 [Abstract] [Full Text]  
• Cannon, C. P. (2005). The IDEAL Cholesterol: Lower Is Better. JAMA 294: 2492-2494 [Full Text]  
• Wartofsky, L. (2005). Update in Endocrinology. ANN INTERN MED 143: 673-682 [Full Text]  
• Williams, K. J., Tabas, I. (2005). Lipoprotein Retention--and Clues for Atheroma Regression. Arterioscler. Thromb. Vasc. Bio. 25: 1536-1540 [Abstract] [Full Text]  
• Ong, H.T. (2005). The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. QJM 98: 599-614 [Abstract] [Full Text]  
• Auer, J., Lamm, G., Eber, B., Cannon, C. P., Murphy, S. A., Braunwald, E., Ravnskov, U., Rosch, P. J., Sutter, M. C., Modest, G. A., Southern, W., LaRosa, J. C., Grundy, S. M., Waters, D. D. (2005). Intensive lipid lowering with atorvastatin in coronary disease.. NEJM 353: 93-96 [Full Text]  
• Lerman, B. B., Devereux, R. B., Okin, P. M. (2005). An Introduction. J Am Coll Cardiol 45: B2-B3 [Full Text]  
• Beckley, E. T. (2005). Cardiologists Share CVD Risk-Reduction Research. DOC News 2: 1-7 [Full Text]  
• (2005). Lower LDL Target for Stable CHD Patients?. Journal Watch Cardiology 2005: 1-1 [Full Text]  
• (2005). Are Lower LDL Targets Beneficial in Patients with Stable CHD?. JWatch General 2005: 1-1 [Full Text]